Mina Bissell and colleagues at Berkeley Lab have developed therapeutic compositions and methods related to inhibition of FAM83A as well as methods of diagnosing cancer resistance to EGFR inhibitors.
For details, see the issued U. S. Patent #9,303,088, available at www.uspto.gov.
FOR MORE INFORMATION:
Lee, S., Meier, R., Furuta, S., Lenburg, M., Kenny, P., Xu, R., and Bissell, M. “FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice,” Journal of Clinical Investigation (JCI), 2012, 122(9):3211–3220.
STATUS: Issued U. S. Patent #9,303,088. Available for licensing or collaborative research.
REFERENCE NUMBER: IB-2578